Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570287 | 1.00 | ACHE (0.41) | ACHEMCHR1KDM4EALDH1A1MEN1 | |
| SCHEMBL2570281 | 1.00 | ACHE (0.41) | ACHEMCHR1KDM4EALDH1A1MEN1 | |
| SCHEMBL2571485 | 0.95 | MCHR1 (0.41) | ACHEMCHR1KDM4EALDH1A1MEN1 | |
| SCHEMBL2571487 | 0.95 | MCHR1 (0.41) | ACHEMCHR1KDM4EALDH1A1MEN1 | |
| SCHEMBL3714775 | 0.95 | MCHR1 (0.41) | ACHEMCHR1KDM4EALDH1A1MEN1 | |
| SCHEMBL2571272 | 0.94 | RXFP1 (0.42) | ACHEMCHR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2571276 | 0.94 | RXFP1 (0.42) | ACHEMCHR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4488651 | 0.90 | ACHE (0.45) | ACHEMCHR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4493352 | 0.90 | ACHE (0.38) | ACHEMCHR1KDM4ELTA4H | |
| SCHEMBL4488657 | 0.90 | ACHE (0.45) | ACHEMCHR1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | ACHE 2390/4885MCHR1 2430/4885KDM4E 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.